Incyte Corporation INCY
Regular-session close
After hours · Nov 16, 5:50 PM ET
- YTD
- +21.77%
- 1 year
- +15.48%
- Market cap
- 24.51B
- Revenue (ttm)
- 6.01B
- Profit margin
- 6.71%
- EPS (ttm)
- 1.96
- Shares out
- 203.83M
- P/E ratio
- 61.36
- Forward P/E
- 13.95
- YTD return
- +21.77%
- 1-year return
- +15.48%
- 50-day average
- 119.18
- Volume
- 1.51M
- Avg volume
- 1.62M
- Open
- 121.98
- Previous close
- 120.97
- Day's range
- 119.79 – 122.94
- 52-week range
- 89.25 – 132.60
- Beta
- 0.78
- Analysts
- Buy
- Price target
- 132.25 (+10.0%)
- Earnings date
- Feb 9, 2027
5D -0.92 (-0.76%)
Key statistics
- 200-day average
- 108.92
- Enterprise value
- 20.84B
- PEG ratio
- 10.82
- Price / sales
- 4.08
- Price / book
- 4.35
- Revenue growth
- 14.00%
- Free cash flow
- 1.29B
- Total cash
- 3.85B
- Total debt
- 37.41M
- Return on equity
- 7.84%
- Short % of float
- 8.87%
Fundamental scorecard
12 of 25 checks passed on INCY’s reported financials
12of 25 checks passed
- Value 0 of 5
- Growth 4 of 5
- Profitability 3 of 5
- Financial health 5 of 5
- Dividend 0 of 5
Statements to Sep 30, 2026.
Analyst view
Consensus: buy
- Target (low)
- 100.00
- Target (mean)
- 132.25
- Target (high)
- 157.00
- Strong buy2
- Buy11
- Hold14
- Sell0
- Strong sell1
Next earnings
Feb 9, 2027
Expected Feb 9, 2027. Consensus EPS estimate 1.97.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Feb 9, 2027 | Dec 30, 2026 | 1.90 | — | — | — |
| Oct 29, 2026 | Sep 30, 2026 | -3.93 | -3.60 | +0.33 | +8.40% |
| Jul 28, 2026 | Jun 30, 2026 | 2.15 | 3.09 | +0.94 | +43.72% |
| Apr 28, 2026 | Mar 31, 2026 | 1.34 | 1.81 | +0.47 | +35.07% |
| Feb 10, 2026 | Dec 31, 2025 | 1.90 | 1.80 | -0.10 | -5.26% |
| Oct 28, 2025 | Sep 30, 2025 | 1.66 | 2.26 | +0.60 | +36.14% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Nov 5, 2026 | Leerink Partners | main | Outperform | Outperform |
| Nov 2, 2026 | Bernstein | main | Market Perform | Market Perform |
| Oct 30, 2026 | Wells Fargo | main | Equal-Weight | Equal-Weight |
| Oct 30, 2026 | RBC Capital | main | Sector Perform | Sector Perform |
| Oct 30, 2026 | Barclays | main | Overweight | Overweight |
| Oct 30, 2026 | Evercore ISI Group | main | In-Line | In-Line |
About Incyte Corporation
Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics in the United States, Europe, Canada, and Japan. The company offers JAKAFI for the treatment of myelofibrosis (MF), polycythemia vera, and steroid-refractory acute graft-versus-host disease; ICLUSIG, a kinase inhibitor to treat chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia; MONJUVI/MINJUVI for the treatment of diffuse large B-cell lymphoma and Follicular Lymphoma; NIKTIMVO for the treatment of chronic graft-versus-host disease. It also provides INCA033989 for the treatment of essential thrombocythemia and MF; INCA035784 for the treatment of anti-mutant calreticulin and myeloproliferative neoplasms (MPNs); INCB160058 for the treatment of MPNs; PEMAZYRE, a selective fibroblast growth factor receptor kinase inhibitor for the treatment of unresectable biliary tract cancer, metastatic cholangiocarcinoma, and myeloid/lymphoid neoplasms; ZYNYZ to treat adults with metastatic or recurrent locally advanced Merkel cell carcinoma. The company's clinical stage products include INCB123667 for ovarian cancer; INCB161734 for solid tumors; INCA33890 for cancers; Ruxolitinib cream for atopic dermatitis, hidradenitis suppurativa (HS), and prurigo nodularis; Povorcitinib for HS, nonsegmental vitiligo, prurigo nodularis, and asthma; and INCB00928 for the treatment of fibrodysplasia ossificans progressive. It has collaboration and license agreement with Novartis, Lilly, and Syndax. The company sells its products to specialty and retail pharmacies, hospital pharmacies, and distributors. Incyte Corporation has a clinical trial collaboration with Genmab A/S to evaluate petosemtamab. The company was formerly known as Incyte Genomics Inc and changed its name to Incyte Corporation in March 2003. Incyte Corporation was incorporated in 1991 and is headquartered in Wilmington, Delaware.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- incyte.com
News
Incyte says EU approves oral treatment for chronic skin disease STOP-HS1 And STOP-HS2 Trials Evaluating Safety And Efficacy Of Povofortay In Patients With Moderate To Severe HS Met The Primary Endpoint
Povofortay® (povorcitinib) Approved in Europe as the First Once-Daily Oral Treatment for Adults with Moderate to Severe Hidradenitis Suppurativa
Incyte Maps Post-Jakafi Growth, Targeting Up to $4 Billion in Other Sales by 2030
Incyte Corporation (INCY) Presents at 8th Annual Wolfe Research Healthcare Conference Transcript Natera Enters Into Clinical Collaboration Agreement With Incyte For New Phase II Study In Colorectal Cancer
Natera Announces Clinical Collaboration with Incyte on Interventional Phase II Study in Colorectal Cancer Leerink Partners Maintains Outperform on Incyte, Lowers Price Target to $150
$1000 Invested In Incyte 20 Years Ago Would Be Worth This Much Today Incyte To Present New Data On Its 30 Abstracts At American Society Of Hematology Annual Meeting
Your note
Sign in to keep a note on INCY — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| BAKER BROS ADVISORS L.P. | Beneficial Owner of more than 10% of a Class of Security | Stock Award(Grant) | Jun 29, 2026 | 0 |
| BAKER BROTHERS LIFE SCIENCES L P | Director and Beneficial Owner of more than 10% of a Class of Security | Stock Award(Grant) | Mar 30, 2025 | 0 |
| CAGNONI PABLO J | Officer | Sale | Oct 14, 2026 | 183,200 |
| HOPPENOT HERVE | Director | Sale | Nov 9, 2025 | 329,646 |
| ISSA MOHAMED KHAIRIE | Officer | Stock Award(Grant) | Jul 15, 2026 | 71,797 |
| IYENGAR VIJAY K | Officer | Sale | Jul 15, 2025 | 40,540 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Baker Bros. Advisors, LP | 15.09% | 30,762,330 | 3.70B | Jun 29, 2026 |
| Blackrock Inc. | 9.38% | 19,129,318 | 2.30B | Sep 29, 2026 |
| Vanguard Capital Management LLC | 5.51% | 11,223,062 | 1.35B | Sep 29, 2026 |
| Dodge & Cox Inc. | 4.94% | 10,064,186 | 1.21B | Sep 29, 2026 |
| State Street Corporation | 4.84% | 9,858,289 | 1.19B | Sep 29, 2026 |
| Vanguard Portfolio Management LLC | 3.81% | 7,773,094 | 934.87M | Sep 29, 2026 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Dodge & Cox Funds-Dodge & Cox Stock Fund | 3.90% | 7,953,128 | 956.52M | Jun 29, 2026 |
| VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 2.64% | 5,390,922 | 648.37M | Jun 29, 2026 |
| VANGUARD INDEX FUNDS-Vanguard 500 Index Fund | 2.13% | 4,346,927 | 522.80M | Jun 29, 2026 |
| VANGUARD INDEX FUNDS-Vanguard Small-Cap Index Fund | 1.91% | 3,894,319 | 468.37M | Jun 29, 2026 |
| VANGUARD SPECIALIZED FUNDS-Vanguard Health Care Fund | 1.17% | 2,386,201 | 286.99M | Jul 30, 2026 |
| iShares Trust-iShares Core S&P 500 ETF | 1.11% | 2,269,019 | 272.89M | Sep 29, 2026 |
